# Can Zenas BioPharma justify its $108M quarterly burn?

> A clinical-stage biotech with $673.9M in cash races toward an FDA decision that will make or break its future.
- Title: Can Zenas BioPharma justify its $108M quarterly burn?
- Summary: A clinical-stage biotech with $673.9M in cash races toward an FDA decision that will make or break its future. Zenas has enough cash to reach its May 2027…
- Keywords: zenas biopharma, zbio, obexelimab, igg4-related disease, phase 3 trial, fda approval, cash burn, biotech, clinical pipeline, royalty pharma, going concern, Zenas
- Source: Alphastreet - Earnings Decoded. Market Intelligence Delivered — https://news.alphastreet.com/can-zenas-biopharmas-zbio-clinical-pipeline-justify-its-heavy-cash-burn
- Author: Newsdesk
- Published: 2026-09-23T15:21:36+00:00
- Read time: 2 min
- Topics: zenas biopharma, zbio, obexelimab, igg4-related disease, phase 3 trial, fda approval, cash burn, biotech, clinical pipeline, royalty pharma, going concern
## Zenas burns $108M quarterly on unproven pipeline
The biotech reported Q2 2026 operating expenses of $108.7 million against just $1 million in revenue, posting a net loss of $111.5 million. The company is pre-commercial and betting everything on clinical validation.
## Obexelimab shows strong Phase 3 efficacy
The lead candidate reduced disease flares by 56% versus placebo in IgG4-related disease, met all four secondary endpoints, and had results published in the New England Journal of Medicine. The FDA accepted the application in August 2026.

> Phase 3 INDIGO trial met its primary endpoint with a hazard ratio of 0.44 (p=0.0005), reducing disease flares by 56% versus placebo
## May 2027 FDA decision is the binary catalyst
The PDUFA target action date of May 27, 2027 will determine whether Zenas commercializes obexelimab or faces accelerating cash pressure. Approval unlocks U.S. revenue; rejection forces additional financing.

> FDA PDUFA date of May 27, 2027 is the binary catalyst
## Cash runway aligns narrowly with FDA date
At $80-85 million quarterly burn, the $673.9 million cash position supports approximately 20-21 months of operations. This timeline aligns precariously with the May 2027 PDUFA date, leaving little margin for delay.
## Orelabrutinib faces serious safety headwinds
The second major asset triggered an FDA partial clinical hold in relapsing MS due to elevated liver enzymes and two Hy's Law cases. Additional hepatotoxicity signals in Phase 3 progressive MS trials could eliminate this revenue stream entirely.
## Royalty Pharma deal provides $300M non-dilutive capital
Zenas received $75 million upfront and can access three additional $75 million tranches tied to regulatory milestones. In exchange, Royalty Pharma takes 5.5% of obexelimab net sales, creating permanent revenue drag.

> Royalty Pharma receives 5.5% of net sales of obexelimab products sold by Zenas worldwide
## Going concern doubt underscores binary risk
Auditors expressed substantial doubt about the company's ability to continue as a going concern, standard for pre-commercial biotechs. The investment thesis hinges entirely on obexelimab approval and successful commercialization.
## Key takeaway

Zenas has enough cash to reach its May 2027 FDA decision on obexelimab, but approval is essential to avoid dilutive financing and a going-concern crisis.